KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Preferred Stock Liabilities (2020 - 2021)

Recursion Pharmaceuticals' Preferred Stock Liabilities history spans 2 years, with the latest figure at $448.3 million for Q1 2021.

  • For Q1 2021, Preferred Stock Liabilities rose 122.92% year-over-year to $448.3 million; the TTM value through Mar 2021 reached $448.3 million, up 122.92%, while the annual FY2020 figure was $448.3 million, 122.92% up from the prior year.
  • Preferred Stock Liabilities reached $448.3 million in Q1 2021 per RXRX's latest filing, roughly flat from $448.3 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $448.3 million in Q4 2020 to a low of $201.1 million in Q1 2020.